Trends in Immunotherapy

Case Report

Topical potent corticosteroids and R-CDOP improved mycosis fungoides after 20 years treatment as tinea corporis

Downloads

https://doi.org/10.24294/ti.v6.i1.1398
Hong Nguyen, C. T., Thanh Nguyen, H., Huong Tran, G., Thi Tuyet Ngo, H., & The Van, T. (2022). Topical potent corticosteroids and R-CDOP improved mycosis fungoides after 20 years treatment as tinea corporis. Trends in Immunotherapy, 6(1). https://doi.org/10.24294/ti.v6.i1.1398
Volume 6 Issue 1 (2022)

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Chuyen Thi Hong Nguyen
    Kansai Medical University Department of Dermatology, University of Medicine and Pharmacy at Ho Chi Minh City
  • Huan Thanh Nguyen
  • Giang Huong Tran
  • Hanh Thi Tuyet Ngo
  • Trung The Van

A 62-year-old woman reported with progressive pruritus rash that persisted on her buttocks and extremities for a duration of twenty years. She was initially diagnosed with tinea corporis but then the morphological and histological features were consistent with MF. As MF is considered as a “great imitator”, it is important to emphasize that cutaneous characteristics, skin biopsy, histology, and immunohistology may need to be performed in patients with chronic dermatoses resistant to treatment to rule out the underlying malignancy.

Keywords:

Mycosis Fungoides Pautrier’s Microabscesses

References

  1. Nashan D, Faulhaber D, Stander S, et al. Mycosis fungoides: A dermatological masquerader. British Journal of Dermatology 2007; 156(1): 1–10. doi: 10.1111/j.1365-2133.2006.07526.x
  2. Brunner PM, Jonak C, Knobler R. Recent advances in understanding and managing cutaneous T-cell lymphomas. F1000Research 2020; 9. doi: 10.12688/f1000research.21922.1
  3. Kamijo H, Miyagaki T. Mycosis fungoides and sezary syndrome: Updates and review of current therapy. Current Treatment Options in Oncology 2021; 22(2): 1–14. doi: 10.1007/s11864-020-00809-w
  4. Hodak E, Amitay-Laish I. Mycosis fungoides: A great imitator. Clinics in Dermatology 2019; 37(3): 255–267. doi: 10.1016/j.clindermatol.2019.01.004
  5. Bowman PH, Hogan DJ, Sanusi ID. Mycosis fungoides bullosa: Report of a case and review of the literature. Journal of the American Academy of Dermatology 2001; 45(6): 934–939. doi: 10.1067/mjd.2001.117521
  6. Kneitz H, Bröcker EB, Becker JC. Mycosis fungoides bullosa: A case report and review of the literature. Journal of Medical Case Reports 2010; 4(1): 1–3. doi: 10.1186/1752-1947-4-78